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| INTRODUCTION
Archibold Garrod is considered the founding father of precision medicine. In 1931, he was the first to recognize interpersonal variation in disease development and impact. Garrod noted that "individual cases of any particular disease are not exactly alike; they resemble rather the drawings made from the same model by individual members of a drawing class." 1 Nowadays, precision medicine is becoming more popular because of an increase in electronic clinical data and a decline in genome sequencing costs. 2, 3 In 2012, former UK Prime Minister David Cameron initiated the 100 000 Genomes Project and in 2015
former US president Barack Obama launched the Precision Medicine
Initiative. 4, 5 The aim of both initiatives was to predict the process of disease and to create personalized patient care by gaining more knowledge on genetic variation in disease.
Significant advances have been made thus far, such as the discovery of certain genetic variations that are linked to the effectiveness of a drug or specific genes that predict cancer risk. 6, 7 Nevertheless, the implementation of precision medicine based solely on genomics has proven to be difficult for certain diseases, such as type 2 diabetes. Recently, new efforts have been undertaken to unravel the genetic background of type 2 diabetes by studying not only common gene variants, but also infrequent and rare variants. 8 To date, only 10% of its heritability has been unveiled, which has been referred to as a "geneticist's nightmare" by some experts. 9 Consequently, precision medicine based on a genotyping approach is still far away for type 2 diabetes. Shifting to a phenotyping approach of precision medicine seems a more promising alternative, in particular in the short-term, to improve patients' health outcomes. 10, 11 The US National Institutes of Health defines precision medicine as an emerging approach for disease treatment and prevention that takes into account not only individual variability in genes, but also a patient's environment and lifestyle. 12 Currently, such a phenotyping approach to precision medicine is only sparsely adopted in evidence-based guidelines for diabetes treatment. Barring some exceptions for older people, these guidelines are usually highly standardized. 13, 14 As a first step towards more patient-centred care, the aim of the present study was 3-fold. It aimed: (1) to identify subgroups of people with newly diagnosed type 2 diabetes with distinct glycaemic trajectories; (2) to predict trajectory membership using patient characteristics that are commonly assessed in diabetes primary care; and (3) to validate these findings in a different cohort of patients with type 2 diabetes.
| RESEARCH DESIGN AND METHODS

| Study design and patients
In this retrospective cohort study, patients were selected using the electronic health records (EHRs) of two large Dutch diabetes care networks (DCNs) that routinely collect individual patient data and have been frequently used for research. [15] [16] [17] [18] [19] No ethical approval was needed for the study; as the data used were already available and patients were not physically involved in the research, the study was not subject to the Dutch Medical
Research (Human Subjects) Act.
| Outcome
The outcome of interest was glycaemic control trajectories, based on 
| Predictors
The baseline patients' characteristics were used as potential predic- 
| Statistical methods
To identify systematically the latent trajectories of glycaemic control, latent growth mixture modelling (LGMM) was used. This method allows the clustering of patients into an optimal number of growth trajectories. 21 Full information maximum likelihood was used as a missing data estimation approach. values indicate less ambiguity in trajectory allocation. 28 The usefulness and clinical interpretation of each trajectory model was also taken into account. Analyses were performed using Mplus version 7.1. 29 and are reported according to the Guidelines for Reporting on Latent Trajectory Studies (GRoLTS) checklist. 24 Baseline characteristics were assessed for the development and validation cohorts. Significant differences between cohorts were determined using two-sample t-tests and chi-squared tests. ANOVA and χ 2 tests were used to identify significant differences between glycaemic control trajectories within each cohort. To gain insight into the influence of glucose-lowering drugs and insulin on the patterns of the trajectories, the percentage of patients with oral glucose-lowering drugs and/or insulin prescriptions was compared at baseline and at each follow-up year between the trajectories of the development cohort using chi-squared tests.
For the development and validation of the prediction model, only patients with no missing baseline values were included. A 5-fold cross-validation was performed in the development cohort. Because there is no consensus on the best-performing classifier, several machine learning classification methods were used. 30 The correlations between SBP and DBP, lipid profile characteristics and CVD characteristics were calculated using the Spearman (for non-normally dis- Receiver-operating characteristic (ROC) curves were generated to show the discrimination of the models. did not have an HbA1c measurement after 5 years of follow-up in the validation cohort (Table S1 ). It was therefore decided to restrict follow-up in the development cohort to 4 years and in the validation cohort to 5 years. The median (interquartile range) number of HbA1c measurements during the research period was 2 (2) in the development cohort and 3 (3) in the validation cohort.
| Latent growth mixture modelling
The model with the strongest fit in the development cohort was the 3-trajectory LGMM (Table S2 ). The largest (76.5%) and most stable trajectory showed a pattern of good glycaemic control (HbA1c ≤7%
[53 mmol/mol]) over time ( Figure 1 ). This trajectory was named "stable, adequate glycaemic control." The middle trajectory, including 21.3% of the population, was named "improved glycaemic control,"
because patients in this trajectory adequately responded to glycaemic treatment and subsequently remained stable at a HbA1c level just above 7% (53 mmol/mol). The smallest trajectory (2.2%) showed very high HbA1c at diagnosis of diabetes, but adequately responded to treatment; however, 2 years after diagnosis, HbA1c started to increase again to levels >7% (53 mmol/mol). This trajectory was named "deteriorated glycaemic control." The mean intercepts and slopes for each class are presented in Table S3 . All intercepts and slope growth parameters were statistically significant. The observed individual trajectories and estimated mean trajectory of the threetrajectory model are shown in Figure S1 .
In the validation cohort, a three-trajectory model was also identified based on model fit (Table S4 ) and population trajectory distribution ( Figure 1) . This model was similar in shape and population distribution to the three-trajectory model of the development cohort.
All intercepts and slope growth parameters were statistically significant (Table S3) .
Figures S1-S5 show all fitted trajectory models in the development and validation cohorts with linear and quadratic slopes, in accordance with the GRoLTS guidelines. 24 There were significant differences between trajectories at all time points in the percentages of patients with oral glucose-lowering drugs and insulin prescriptions (P < .0001). Figures S6 and S7 show that more oral glucose-lowering drugs and insulin were prescribed to patients in the deteriorated and improved glycaemic control trajectories compared with the stable, adequate glycaemic control trajectory. Prescription of oral glucose-lowering drugs increased over time in all trajectories.
| Classification into glycaemic control trajectories
In both cohorts, patients in the deteriorated glycaemic control trajectory were more frequently male, current smokers and younger. Their baseline HbA1c, triglycerides and total cholesterol levels were higher compared with the other trajectories ( Table 2) .
After excluding significant correlations between patient characteristics (Table S5) (Table S7) .
Baseline BMI, HbA1c and triglycerides were the most salient characteristics for predicting trajectory membership according to their weight ( Table 3 (Table S9 ). The ROC-AUC was 0.96 ( Figure 2 ). The calibration plot in the validation cohort showed a good fit for all three trajectories ( Figure S8 ). The developed tool can be found on the webpage www.
patientprofiles.nl and provides the opportunity to fill in different BMI, HbA1c and triglyceride values and to view the related trajectory.
| DISCUSSION
In the present retrospective cohort study in patients with newly diagnosed type 2 diabetes treated in primary care, three distinct glycaemic trajectories were identified during the first 5 years after diagnosis:
(1) stable, adequate glycaemic control; (2) improved glycaemic control;
and (3) Both studies identified four glycaemic trajectories, which had notable similarities to the trajectory patterns we observed in the present study. The similarities between the previous and present studies were most notable for the "stable, adequate glycaemic control" trajectory.
In both previous studies, this trajectory was identified and included 83% of their patients, slightly higher than the 72% we found. These results indicate that current practice enables a majority of patients to reach and maintain recommended glycaemic control levels. The present study shows that this group of patients can be identified at diagnosis by applying a model that has a high PPV and NPV.
These findings have important implications for more precision medicine in type 2 diabetes. The main goal of precision medicine is to develop models that can predict disease development or disease outcomes in order to tailor treatment. 3 Our model uses three relatively simple clinical characteristics, BMI, HbA1c and triglycerides, to divide patients into three groups, each with different future glycaemic trajectories. Predicting patients' future glycaemic control enables care professionals to provide tailored diabetes management. For patients classified in the stable, adequate glycaemic control group, for example, less intensive monitoring might suffice, whereas patients classified in the deteriorated glycaemic control group could benefit more from frequent monitoring. Previous research suggests that less frequent monitoring of patients with stable, adequate glycaemic control -that is, biannual instead of quarterly check-ups by a general practitioner -is possible without negative effects on health, allowing considerable cost reductions. 33 More generally, our model enables tailoring of a range of diabetes care components to patients' care needs, including pharmacotherapy, lifestyle advice and self-management support. Abbreviations: ACR, albumin-to-creatinine ratio; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; SBP, systolic blood pressure. Percentages have been rounded and might not total 100. a Percentages are out of total with recorded values.
In the present study we applied a unique approach by combining
LGMM with machine learning techniques. There were three followup HbA1c measurements in the development cohort and four in the validation cohort, allowing the identification of heterogeneity in future glycaemic response. Prescription of glucose-lowering drugs and insulin may have influenced the patterns of the trajectories.
HbA1c levels in the stable, adequate and improved glycaemic control trajectories remained stable or improved, possibly because of an increase in oral and insulin prescriptions over time. In the deteriorated glycaemic control trajectory, however, HbA1c increased, despite an increase in glucose-lowering drugs and insulin prescriptions. Disease progression or difficulties adhering to drug treatment and healthy lifestyle could be explanations for this. 34, 35 The external validation is an important strength of the present study, considering that many research findings are based solely on the basis of a single study. 36 A limitation was that both cohorts consisted of a predominantly white population. When compared with white populations, other races tend to have higher HbA1c values, 37 and their inclusion might have resulted in glycaemic control trajectories that differed in size and shape. One of the previous studies that examined latent glycaemic control trajectories 31 included a mixedrace population, with~50% non-white participants; however, as stated before, the identified trajectories in that study were similar to the trajectories in the present study.
So far, predictive models and tools based on machine learning techniques have not been widely used in clinical decision support systems. 38 One of the reasons for this could be that data obtained from EHRs are considered a byproduct of healthcare delivery, rather than a resource to improve its performance. 39 In addition, most machine learning models are complex and difficult to interpret because they depend heavily on aspects related to feature distribution, data availability and data representation. 40 In the present study we built and validated a simple and interpretable algorithm with excellent accuracy. Despite the high PPV and NPV in the stable, adequate glycaemic control trajectory, the PPV in the deteriorated glycaemic control trajectory was only 45.8% in the validation cohort.
This implies that more than half the patients classified in this trajectory do not belong there (false-positives), which is a point for further refinement. The counterpart is that the NPV is high, implying that membership of this trajectory can be ruled out with high certainty.
In conclusion, only three patient characteristics (BMI, HbA1c and triglycerides) are needed to accurately predict glycaemic response of patients with newly diagnosed type 2 diabetes. The model can be used in practice as a quick, easy and accurate tool to determine patients' care needs and provide tailored diabetes treatment.
ACKNOWLEDGMENTS
The study was supported by a research grant from Novo Nordisk B.V. The funding body did not play a role in the study design, the writing of the manuscript, or the decision to submit the manuscript for publication. The views expressed are those of the authors and not necessarily those of Novo Nordisk B.V. The authors thank Dario Dotti, Maastricht University, for assisting in the development of the prediction models.
Conflict of interest
All authors declare: no support from any organization for the submitted work: no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Author contributions
DH, AE, MB, DR and NS conceived and designed the study. DH and SH did the data extraction. DH, SK, and MP did the analyses. DH wrote the first draft of the study. All authors contributed to the interpretation of results and drafting of the manuscript. All authors read and approved the final manuscript. DH is the guarantor. 
